An observational study in Spinal Muscular Atrophy, sponsored by Hangzhou Jiayin Biotech Ltd. Enrolling by invitation at 1 site in China. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2025-03-05.
Sponsored by Hangzhou Jiayin Biotech Ltd · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Muscular Atrophy, Spinal with a site in China — 6 open to participants now, 13 under way, 4 of them phase 3. Muscular Atrophy, Spinal · China.
Among the 23 studies in Muscular Atrophy, Spinal with a site in China, this one is one of 4 that started in 2025, is one of 7 observational ones, reaches primary completion later than 10 of the 12 other live ones, and was the 16th registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.
Browse Muscular Atrophy, Spinal studies →6 of the 23 studies in Muscular Atrophy, Spinal with a site in China are open now. Recruiting first, the newest first:
Biogen · Sites in China, United States, Brazil and 2 more countries
Ages 15–60
Biogen · Sites in China, United States, Australia and 4 more countries
Ages 0 days–42 days
GeneCradle Inc · Sites in China
Ages 0 mo–6 mo
Wan-Jin Chen · Sites in China
Ages 1 wk–70 yrs · Healthy volunteers
Hangzhou Jiayin Biotech Ltd · Sites in China
Ages 1 days–2 yrs
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.
This study: 1 Month and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 7
First in 2016; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 18 is below the median of 139 across 114 observational studies indexed under Muscular Atrophy, Spinal.
Median enrollment 35 across the 16 interventional studies, 200 across the 7 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 23 have an industry lead sponsor. The 10 most frequent:
Hangzhou Jiayin Biotech Ltd is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
Hangzhou Jiayin Biotech Ltd has 2 studies filed under Muscular Atrophy, Spinal — fewer than ten, so there is no comparison to draw.
5 of the studies in Muscular Atrophy, Spinal with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06971094Phase 3GeneCradle IncSafety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III | 2026-12-31 |
| NCT05824169GeneCradle IncEvaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients | 2026-12 |
| NCT07822711Peking University Third HospitalEffects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA | 2027-01-15 |
| NCT05042921BiogenPediatric Spinal Muscular Atrophy (SMA) China Registry | 2027-09-02 |
| NCT06288230Lantu BiopharmaAn Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 23 studies in Muscular Atrophy, Spinal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An Open-label, Long-term Follow-Up Study to Evaluate the Safety and Tolerability of Gene Therapy with EXG001-307 in SMA1 patients ,who joined the parent study (EXG001-307-102)
This study plans to enroll type 1 SMA patients who have previously received EXG001-307 treatment in the parent trial EXG001-307-102 to observe the long-term safety and efficacy of gene therapy with EXG001-302.
The first year of long-term follow-up will be conducted every 3 months ; In the second year, follow-up visits will be conducted every six months, with telephone follow ups at 15 and 21 months during this period; From 3 to 5 years after gene therapy, follow up by phone every six months and follow on on site once a year.
Type 1 SMA patients who have previously used EXG001-307 in trial EXG001-307-102 .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention, only for observational studies
long-term safety:Assess the types, severity, and incidence of serious adverse events (SAEs) and adverse events of particular concern (AESIs)
Assess the types, severity, and incidence of serious adverse events (SAEs) and adverse events of particular concern (AESIs)
Time frame: 4 years
Evaluate the long-term effectiveness of EXG001-307 treatment: assess the achievement of exercise milestones based on the scale
The achievement of new milestones in the third edition of the Berry Infant and Child Development Scale (BSID-III): Doctors need to evaluate whether patients can achieve the following milestones: head control:Can children keep their heads upright for at least 3 seconds without support; sitting without assistant:Can children sit up alone for at least 5 seconds without support; standing with assistant:Can children use chairs or other convenient objects as support to stand up on their own; standing without assistant:Can the child stand alone for at least 3 seconds after the evaluator releases the child's hand; walking with assistant:Can children make coordinated and alternating stepping movements while walking; walking without assistant:Can children walk at least three steps without support, even if their gait is stiff and unstable;
Time frame: 4 years
Evaluate the long-term effectiveness of EXG001-307 treatment: evaluate event free survival rate
Event free survival rate: The event free survival rate refers to the proportion of subjects who did not die and did not require permanent mechanical ventilation with a ventilator. Permanent mechanical ventilation refers to the need for tracheotomy to maintain ventilation in irreversible emergencies or after emergency resolution, or the need to rely on Bipap mechanical ventilation support for ≥ 16 hours per day for more than 3 consecutive weeks, or tracheal intubation for ≥ 3 weeks; Researchers evaluate patients by examining their daily use of ventilators.
Time frame: 4 years
Evaluate the immunogenicity of EXG001-307 after treatment, including measuring the titers of anti-AAV9-ADA and anti-SMN-ADA antibodies.
After blood collection, send it to the central laboratory to complete the following antibody testing: the titers of anti-AAV9-ADA and anti-SMN-ADA antibodies (until two consecutive negative results);
Time frame: 4 years
Evaluate the distribution of viral vectors after treatment with EXG001-307: detect the level of vector genome in saliva, feces, and urine samples of subjects.
Carrier distribution: Genomic level of carriers in saliva, urine, and fecal samples (up to two consecutive negative resultst);
Time frame: 4 years
Exploratory objective: To calculate the proportion of subjects receiving other SMA treatments during the trial period
Calculate the proportion of subjects receiving other SMA treatments to the total number of subjects.
Time frame: 4 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2025; primary completion for Sep 2030, 66 months later.
Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 66 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hangzhou Jiayin Biotech Ltd